/cloudfront-us-east-1.images.arcpublishing.com/eluniverso/VFRROMXEKJAW5GIYUJQKXLHMU4.jpg "Datos de Pfizer and Israel determine the loose holidays of COVID-19 | International | Notice")
The founder of BioNTech was optimistic about his vacancies during an interview.
The optimism regarding the vacuas against the COVID-19 aumenta a medida que se conocen los datos de los primeros pais en enmunizar massivamente, Israel va a la cabeza en cuant a la vacunación. Ugur Sahin, the founder and CEO of BioNTech, the company that, together with Pfizer, logs the approval of the major regulatory agencies for its munitions, has been optimistic during a interview with the German diary Picture.
“The number of people for whom PCR is positive and which, for that matter, are potentially contagious, is reduced to 92 per cent after the evacuation”, Sahin Indicates the latest massive study in Israel. Sahin announced that Pfizer’s vacancy in BioNTech “protege against the Mayor of known mutations, including the B.1.1.7. “, The British variant.
The founder of BioNTech also revealed that there is a possibility that it will need to administer a third dose of the current vaccine, in anticipation of the appearance of new variants. Do not hesitate to apply a dose dose “every year or every year” as a form of combating coronavirus.
Israel leads world evacuation
Sahin’s optimism is based on the largest vacancy study in Israel, with 1.2 million students. Between 14 and 20 days after the first dose and the most days after the second dose, the estimated efficacy of the vaccine era from 46 and 92 per cent.
Israel is leading the world in the 4.8 million vacancy campaign involving the first dose and more than 3.5 in the second half of the number of new residents. (I)